Biomarin Pharmaceutical Inc (BMRN)
Return on total capital
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 205,898 | 165,546 | -60,013 | -19,688 | -71,351 |
| Long-term debt | US$ in thousands | 593,095 | 1,083,020 | 1,079,080 | 1,075,140 | 486,238 |
| Total stockholders’ equity | US$ in thousands | 4,951,550 | 4,603,160 | 4,265,670 | 4,100,930 | 3,122,380 |
| Return on total capital | 3.71% | 2.91% | -1.12% | -0.38% | -1.98% |
December 31, 2023 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $205,898K ÷ ($593,095K + $4,951,550K)
= 3.71%
The return on total capital for Biomarin Pharmaceutical Inc has shown a positive trend from -1.98% in 2019 to 3.71% in 2023. This indicates an improvement in the company's ability to generate profits relative to its total invested capital over the years. The steady increase in the return on total capital suggests that the company has been more efficient in utilizing its capital resources to generate returns for its investors. Overall, the positive trend in the return on total capital indicates a positive performance and financial health of Biomarin Pharmaceutical Inc.
Peer comparison
Dec 31, 2023